Corporate Overview

Edesa Biotech Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs.

Our lead product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis, a common, potentially debilitating condition and occupational illness. The topical therapy employs a novel mechanism of action, and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in contact dermatitis patients. We are currently enrolling subjects in a Phase 2b clinical study evaluating EB01.

We also hold exclusive rights to two late-stage monoclonal antibodies, designated as EB05 and EB06, which block certain immune signaling proteins, known as TLR4 and CXCL10. These molecules are associated with a broad range of diseases, including the inflammation associated with infectious diseases. Due to the global health emergency, we have prioritized the development of EB05 as a potential treatment for acute respiratory distress syndrome (ARDS) in hospitalized COVID-19 patients.

Edesa is a clinical-stage biopharma company focused on inflammatory and autoimmune diseases

Financial Reports

Investors News

News Alerts

Investors Relations

Edesa Biotech, Inc.
Attn: Investor Relations
100 Spy Court
Markham, ON L3R 5H Canada

(289) 800.9600



Legal Counsel

Fasken Martineau DuMoulin LLP


Transfer Agent

Computershare Investor Services Inc.
100 University Avenue, 8th Floor
Toronto, Ontario M5J 2Y1

Tel: (800) 564-6253